Stonepine Capital Management, LLC: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1440771) · Explore on the interactive board
Stonepine Capital Management, LLC disclosed 72 US equity positions worth $131.4m in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 17, 2026). Its largest position is VSTM at 9.7% of the reported book, followed by EOLS, TENX. The top ten holdings are 55.3% of the book, and the portfolio behaves like about 24 equal-weight positions. Versus the prior filing it opened 19 new positions, added to 23, reduced 25 and exited 9. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Stonepine Capital Management, LLC own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 19 new, 23 added, 25 reduced, 9 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | VSTM VERASTEM INC | Healthcare | 9.7% | $12.8m | 3,349,627 | 1% | added |
| 2 | EOLS EVOLUS INC | Healthcare | 8.4% | $11.0m | 1,590,162 | -10% | reduced |
| 3 | TENX TENAX THERAPEUTICS INC | 7.3% | $9.6m | 660,000 | -32% | reduced | |
| 4 | NKTR NEKTAR THERAPEUTICS | Healthcare | 6.4% | $8.4m | 120,654 | 42% | added |
| 5 | ADMA ADMA BIOLOGICS INC | Healthcare | 4.7% | $6.2m | 740,000 | 0% | held |
| 6 | CAMP CAMP4 THERAPEUTICS CORP | 4.6% | $6.1m | 1,389,622 | 0% | held | |
| 7 | ELOXX PHARMACEUTICALS INC | 4.2% | $5.5m | 397,160 | – | new | |
| 8 | KZIA KAZIA THERAPEUTICS LTD | 3.7% | $4.9m | 345,179 | 0% | held | |
| 9 | INDV INDIVIOR PHARMACEUTICALS INC | Healthcare | 3.1% | $4.1m | 100,000 | – | new |
| 10 | CRBP CORBUS PHARMACEUTICALS HLDGS | Healthcare | 3.0% | $4.0m | 425,000 | 11% | added |
| 11 | MSLE SATELLOS BIOSCIENCE INC | 2.8% | $3.7m | 491,624 | 392% | added | |
| 12 | ZVRA ZEVRA THERAPEUTICS INC | 2.8% | $3.7m | 258,701 | -46% | reduced | |
| 13 | ABEO ABEONA THERAPEUTICS INC | Healthcare | 2.6% | $3.4m | 557,284 | -25% | reduced |
| 14 | EDSA EDESA BIOTECH INC | 2.4% | $3.2m | 456,439 | 1421% | added | |
| 15 | CABA CABALETTA BIO INC | Healthcare | 2.2% | $2.9m | 917,100 | 1734% | added |
| 16 | ANTX AN2 THERAPEUTICS INC | 2.0% | $2.7m | 551,692 | -23% | reduced | |
| 17 | XLO XILIO THERAPEUTICS INC | 1.6% | $2.2m | 225,994 | 252% | added | |
| 18 | ACET ADICET BIO INC | 1.6% | $2.1m | 245,518 | 11% | added | |
| 19 | TELA TELA BIO INC | 1.5% | $2.0m | 2,662,427 | 2% | added | |
| 20 | AYTU AYTU BIOPHARMA INC | 1.5% | $2.0m | 912,921 | 15% | added | |
| 21 | CRIS CURIS INC | 1.3% | $1.7m | 3,312,185 | -11% | reduced | |
| 22 | SPRB SPRUCE BIOSCIENCES INC | 1.2% | $1.6m | 28,795 | – | new | |
| 23 | OKYO OKYO PHARMA LTD | 1.0% | $1.3m | 862,996 | 2% | added | |
| 24 | KTTA PASITHEA THERAPEUTICS CORP | 0.9% | $1.1m | 2,201,468 | 165% | added | |
| 25 | SOL-GEL TECHNOLOGIES LTD | 0.8% | $1.1m | 14,469 | -48% | reduced | |
| 26 | LUNG PULMONX CORP | Healthcare | 0.8% | $1.1m | 815,436 | 6% | added |
| 27 | XFOR X4 PHARMACEUTICALS INC | 0.8% | $1.1m | 224,989 | -33% | reduced | |
| 28 | INAB IN8BIO INC | 0.7% | $980.4k | 695,287 | 5% | added | |
| 29 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 0.7% | $973.5k | 50,000 | – | new |
| 30 | QUOIN PHARMACEUTICALS LTD | 0.7% | $965.5k | 199,486 | 273% | added | |
| 31 | MXCT MAXCYTE INC | Healthcare | 0.7% | $924.5k | 751,606 | -25% | reduced |
| 32 | PHAT PHATHOM PHARMACEUTICALS INC | Healthcare | 0.7% | $922.4k | 85,010 | 70% | added |
| 33 | AZITRA INC | 0.7% | $886.9k | 5,285,476 | – | new | |
| 34 | CNTB CONNECT BIOPHARMA HLDGS LTD | 0.7% | $866.9k | 364,254 | 18% | added | |
| 35 | HELP CYBIN INC | 0.7% | $854.5k | 129,280 | -4% | reduced | |
| 36 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 0.6% | $834.8k | 25,000 | – | new |
| 37 | IKT INHIBIKASE THERAPEUTICS INC | 0.6% | $804.2k | 396,179 | -59% | reduced | |
| 38 | ZNTL ZENTALIS PHARMACEUTICALS INC | Healthcare | 0.6% | $783.7k | 161,583 | -40% | reduced |
| 39 | CTMX CYTOMX THERAPEUTICS INC. | Healthcare | 0.6% | $768.8k | 205,000 | 2% | added |
| 40 | NVCT NUVECTIS PHARMA INC | 0.6% | $735.6k | 40,000 | – | new | |
| 41 | CBIO CRESCENT BIOPHARMA INC. | 0.5% | $720.0k | 40,000 | -53% | reduced | |
| 42 | PMVP PMV PHARMACEUTICALS INC | Healthcare | 0.5% | $718.4k | 536,086 | -24% | reduced |
| 43 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 0.5% | $713.8k | 7,500 | – | new |
| 44 | RADIOPHARM THERANOSTICS LTD | 0.5% | $670.5k | 51,000,000 | 0% | held | |
| 45 | OKUR ONKURE THERAPEUTICS INC | 0.5% | $595.9k | 130,684 | -1% | reduced | |
| 46 | NERVGEN PHARMA CORP | 0.4% | $559.7k | 271,678 | – | new | |
| 47 | CALC CALCIMEDICA INC | 0.4% | $544.9k | 622,432 | – | new | |
| 48 | ARVN ARVINAS INC | Healthcare | 0.4% | $498.6k | 60,000 | 118% | added |
| 49 | BIOA BIOAGE LABS INC | 0.4% | $490.2k | 20,000 | -60% | reduced | |
| 50 | IRD OPUS GENETICS INC | 0.3% | $414.0k | 100,718 | 47% | added |
What did Stonepine Capital Management, LLC sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| XOMA ROYALTY CORPORATION | 42.2% | $2.2m |
| SRZN SURROZEN INC | 18.6% | $961.4k |
| VRCA VERRICA PHARMACEUTICALS INC | 10.2% | $527.6k |
| CADL CANDEL THERAPEUTICS INC | 9.7% | $502.2k |
| ESTA ESTABLISHMENT LABS HLDGS INC | 6.6% | $340.7k |
| JANX JANUX THERAPEUTICS INC | 5.4% | $278.0k |
| OABI OMNIAB INC | 5.0% | $257.6k |
| ELDN ELEDON PHARMACEUTICALS INC | 2.1% | $107.8k |
| BCAB BIOATLA INC | 0.2% | $10.5k |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 47.1% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Stonepine Capital Management, LLC's portfolio?
Across every quarter Stonepine Capital Management, LLC has filed, its median largest position is 12.6% of the book and its median top-ten weight is 59.8%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 13.0 completed holding spells, the median lasted 1.0 quarters; 72.0 positions are still open and their final length is unknown.